drugset
drugset / Trial / NCT02432690

A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation

NCT02432690 ↗

Phase 2 Terminated 13 enrolled Sumitomo Pharma America, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This was an open-label, single-arm, Phase II study in which amcasertib (BBI503) was administered to adult, asymptomatic patients with recurrent ovarian cancer who had elevated CA-125.

Timeline

Start
2015-06
Primary completion
2017-01-02
Completion
2017-01-02

Drugs

EvaluationDrugModalityDoseRoute
Subject AMCASERTIB Small molecule 200 mg Oral

Indications

ovarian cancer